VCAM-1 imaging in ovarian cancer may improve survival

September 17, 2013

Homing in on vascular cell adhesion molecule-1 (VCAM-1) expression in metastatic ovarian cancer with SPECT could gauge response to therapy and potentially improve survival, according to a study published Sept. 12 in the Journal of Nuclear Medicine.

Survival rates of ovarian cancer, currently the deadliest gynecologic cancer, are a dismal 30 to 40 percent at the five-year mark. However, this is mostly due to the advanced stage of the cancer upon diagnosis. Inhibition of VCAM-1 expression through chemotherapy has been shown to decrease tumor burden and improve prognosis. Jennifer M. Scalici, MD, from the department of Obstetrics and Gynecology, University of Virginia in Charlottesville, Va., and colleagues evaluated VCAM-1 targeted SPECT/CT as a biomarker for response to standard platinum chemotherapy.